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ABSTRACT
Diabetes mellitus (DM) is an increasing health challenge. Control of blood glucose level, as
measured by level of glycated hemoglobin (HbA1c), is used as an indicator of glycemic control and
potential risk of diabetic complications. This study aimed to investigate the extent of glycemic
control among type 2 diabetic patients and to determine factors associated with increasing levels of
HbA1c.A total of 380 patients were interviewed using a questionnaire prepared for this cross –
sectional study. The patients were recruited from a diabetic clinic in Nablus, Palestine. Clinical
laboratory data and HbA1c values were obtained from medical files of the patients while
demographic information were obtained through face-to-face interview. The participants had a
mean ± standard deviation (SD) age of 60 ± 10 years. A total of 71 (18.7%) participants were less
than 50 years of age. The participants had a mean body mass index (BMI) of 32.7± 6 Kg/m2 with
more than two thirds were considered obese with a BMI of ≥ 30 Kg/m2. The studied patients have a
mean ± SD of HbA1c of 8.3± 1.8. The median of HbA1c was 8.05 with interquartile range of (First
quartile (Q1) = 6.93; Third quartile (Q3) = 9.5). The majority of studied patients (278; 73.2%) had
HbA1c value above 7%. The mean ± SD healthcare index (HCI) of the studied patients was 4.29 ±
1.49. Univariate analysis showed that age (p<0.01), total cholesterol (p<0.01), low density
lipoprotein (LDL) (p<0.01), high density lipoprotein (HDL) (p=0.028), HIC (p<0.01), and type of
therapeutic regimen (p<0.01) were significantly correlated with HbA1c. Multivariate analysis
indicated that younger age, lower HDL values, combination therapy with insulin were significantly
associated with increasing levels of HbA1c.High proportion of patients recruited for this study had
poor glycemic control. Younger age was associated with higher HbA1c values which necessitates
urgent and immediate medical intervention at the primary healthcare level.
Keywords: Glycemic Control, Palestine, Diabetes Mellitus, Multivariate Analysis.
BACKGROUND
Diabetes mellitus (DM) is an increasing
global and regional public health challenge
[1-4]. It's estimated that there was about
381.8 million adults with DM worldwide in
2013 and the number is expected to increase
to 55% by 2035 [2]. Diabetes mellitus affects
all regions in the world. However, the
prevalence of DM in the Middle East and the
projections of DM for the future are
prominent for the Middle East Arab region
[5]. Despite the rising rates of DM in the
Middle East Arab region, research activity on
DM in the Arab countries is lagging behind

globally and regionally when compared with
neighboring non-Arab countries such as
Turkey or Iran [6, 7]. In Palestine, a small
area in the Middle East, research on
prevalence of DM and its complications are
scarce and sometimes relatively old [8, 9].
Some recently published reports on DM from
Palestine discussed specific aspects of DM in
certain categories of patients such as patients
with schizophrenia [10, 11].
Diabetes
mellitus
has
major
complications on patient’s health which
could adversely affect him/her financially,
and drain the governmental budget allocated
for health [12, 13]. It has been shown that
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good glycemic control can help patients
avoid serious diabetic complications [14-17].
A trustful and commonly used indicator of
glycemic control is glycated hemoglobin
concentration (HbA1c) which is a
presentation of blood glucose levels in the
previous 2 – 3 months [18-20]. It has been
suggested by the American Diabetes
Association that HbA1c level less than 7 % is
a good indicator of optimal glucose control
and HbA1c level more than 7% as an
indicator of poor glycemic control [21].
Higher levels of HbA1c were significantly
associated with dyslipidemia particularly
lower HDL values [22-25].
Several studies have been carried out
and published about the status of glycemic
control among diabetic patients in several
regional countries such as Jordan, Saudi
Arabia, Iran, and others [26-29]. The
differences in life style, cultural habits,
healthcare system, and awareness in diabetes
– related health issues create differences in
prevalence and type of factors associated
with glycemic control among different
countries. In Palestine, the government is the
main provider for health services, particularly
for patients with chronic diseases such as
DM. The unstable political and financial
situation of the Palestinian national authority
is a major hindering factor for the provision
of continuous high quality services to
Palestinian patients. This increases the
burden on patients with DM who needs
continuous monitoring and follow up to
achieve glycemic control. A considerable
amount of literature has been published on
diabetic patients in Palestine [6, 10, 30-39].
To our minds far too little attention has been
paid to the prevalence of glycemic control
among diabetic patients. Therefore, this
cross-sectional study investigates the
prevalence of glycemic control among a
sample patients with type 2 DM attending a
major governmental primary healthcare unit
in Nablus, Palestine. Furthermore, the study
will investigate the clinical and demographic
factors that are significantly associated levels
of HbA1c above 7%. Such study will help
promote the health status of diabetic patients
and decreasing the consequent economic loss

due to treatment of diabetic complications if
healthcare providers were aware of the
prevalence of glycemic control and the health
mechanisms required to optimize glycemic
control among diabetic patients.
METHODS
Study design and settings
This was a cross-sectional descriptive
study that involved patients with type 2 DM
attending Al-Makhfia healthcare center for
regular follow up. Al-Makhfia healthcare
center is the largest governmental primary
healthcare center in Nablus, North Palestine.
The center provides health services for
diabetic patients. There are more than 2000
diabetic patients registered in this center who
receive regular medical follow up and get
their medications dispensed at the center for
minimum charges.
The study was carried out on patients
who were attending the clinic and were
waiting to see the physician. The followings
were used as inclusion criteria for the study:
patients with type 2 DM, willingness to
participate in the study, physically and
mentally able to provide all data required for
the study, had regular follow up at AlMakhfia diabetic clinic, and had done all
laboratory tests required for study at least
once during the last three months at AlMakhfia clinic. When there were two values
for any clinical laboratory test in the past
three months, the mean value was calculated
and used in the analysis. Exclusion criteria
were the followings: type 1 diabetic patients
and patients with missing HbA1c value in the
past 3 months. The sample size was
estimated to be 380, using Raosoft sample
size calculator [40] assuming a margin of
error to be 5% and a confidence level of
95%.
Two of the investigators attended the
clinic daily for three consecutive months for
data collection. One of the investigators
approached the patients who were in the
waiting area and asked for their permission to
participate in the study. Patients who gave
consent to participate were asked to sign a
consent form in accordance with the ethical
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requirements. The first investigator carried a
face –to– face interview with the patients
using a pre-designed questionnaire that
involved questions pertaining to the
demographic information, health seeking
behavior, and clinical information pertaining
to duration of DM, body weight, height, and
blood pressure. The second investigator was
in charge of examining the medical file of the
patient and extraction of the clinical and
laboratory information which included the
level of HbA1c, lipid profile, other comorbid diseases, and any other relevant
laboratory information such as renal or liver
function tests. Approval of the study by the
Institutional Review Boards (IRB) and the
Palestinian health authorities was obtained
before the initiation of this study. Written
approval was obtained from the Ministry of
Health to allow the investigators to get access
to the patients and their records at AlMakhfia primary healthcare center. The data
were collected in the period between
September and December 2016.
Health Care Index (HCI)
In order to assess the patients’ healthcare
seeking behavior and management pattern,
Health Care Index (HCI) was used. The HCI
was based on the followings: frequency of
diabetic clinic visits, number of blood
pressure measurements, number of weight
measurements, weather the patient did ECG,
funds exam, proteinuria, and lipid profile test
during the last six months. The first three
variables were assessed according to the
median value, if the patient had frequency of
the variable above the median, then he/ she
will take 1 point in the scoring system and if
the frequency is less than the median, then
he/she will take a zero in the scoring system.
The last four variables were assessed by yes
or no. If the patient performed the test at least
once during the last six months, then he/she
will get 1 point, if not, then he/ she will get
zero points. The overall of these seven
variables were summed (the highest score is
seven and the least score is zero).
Regarding lipid profile results, normal
values were adopted based on what the
Palestinian MOH laboratory values. Total

cholesterol was considered to be normal if it
was less than 200 mg/ dL, LDL was normal
if it was <100 mg/ dL, normal triglycerides if
it was <150 mg/ dL. Regarding HDL, for
males the target HDL is ≥ 40 mg/ dL, for
females it should be ≥50 mg/dL.
Statistical Analysis
Statistics used in this manuscript was
performed using SPSS version 21. Mean ±
SD (standard deviation) and median (first
quartile – third quartile) were used to present
continuous data while frequency and
percentage were used to present categorical
data. Normality test for the HbA1c values
was performed using Komogrove – Smirnove
test. In this study, the HbA1c value were not
normally distributed and non-parametric tests
were used to perform analysis. For univariate
analysis, Spearman correlation was used to
test for significant correlation between
HbA1c values and various continuous
variables while Mann – Whitney and Kruskal
Wallis were used to test for significant
difference between categorical variables (e.g.
gender) in HbA1c values. For multivariate
analysis, linear logistic regression was used
with HbA1c value as dependent variable.
Only variables with significant results in
univariate analysis were used in logistic
analysis. Significance was set at values less
than 0.05.
RESULTS
Demographic characteristics
A total of 380 patients with type 2 DM
participated in the study. Females (220;
57.9%) constituted more than half of the
participants. The mean age of the patients
was 60±10 years with 71 (18.7%)
participants were less than 50 years of age.
The mean duration of DM in studied patients
was 11.2 ± 8.2 years with 115 (30.3%) of
studied patients had an illness duration of
less than five years. The mean BMI of the
participants was 32.7± 6 Kg/m2 with more
than two thirds considered obese (their BMI
≥ 30 Kg/m2). The majority of participants
were non-smokers 280 (73.7%), and had no
university or college education (332; 87.4%).
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Details about demographic characteristics of
the study sample are shown in Table 1.
Table (1): Demographic and clinical characteristics of study patients.
Variable
Age (years)
Mean ± SD
Median (Q1 – Q3)
Age (years) category
<50
50-59
60-69
≥ 70
Duration (years)
Mean ± SD
Median (Q1 – Q3)
Duration (years)
category
<5
5-10
10-15
≥ 15
BMI (kg/m2) category
Mean ± SD
Median (Q1 – Q3)
BMI (kg/m2)
<25
25-30
> 30
HbA1c (%)
Mean ± SD
Median (Q1 – Q3)
HbA1c (%) category
≤7
>7
Gender
Male
Female
Tobacco
Yes
No
Treatment type
Not defined
Oral agent
Insulin
Insulin + oral agents
Level of education
Illiterate
≤ high school
>High school
Hypertension
Yes
No

Statistics
60 ± 10
60 (53 – 67)
71 (18.7)
130 (34.2)
128 (33.7)
51 (13.4)
11.2 ± 8.2
10 (5 – 16)
115 (30.3)
105 (27.6)
58 (15.3)
102 (26.8)
32.7 ± 6
31.95 (28.83 –
36.20)
22 (5.8)
96 (25.3)
262 (68.9)
8.3 ± 1.8
8.05 (6.93 – 9.5)
102 (26.8)
278 (73.2)
160 (42.1)
220 (57.9)
100 (26.3)
280 (73.7)
7 (1.8)
151 (39.7)
78 (20.5)
144 (37.9)
50 (13.2)
282 (74.2)
48 (12.6)
255 (67.1)
125 (32.9)

Variable
Co-morbid conditions
Yes
No
HCI score
Mean ± SD
Median (Q1 – Q3)
HCI score
≤3
≥4
Total Cholesterol
Mean ± SD
Median (Q1 – Q3)

Total Cholesterol
(category)
Normal
Abnormal
Triglyceride
Mean ± SD
Median (Q1 – Q3
Triglyceride
Normal
Abnormal
LDL
Mean ± SD
Median (Q1 – Q3)
LDL (category)
Normal
Abnormal
HDL female
Mean ± SD
Median (Q1 – Q3)
HDL female
Normal
Abnormal
HDL male
Mean ± SD
Median (Q1 – Q3)
HDL male
Normal
Abnormal

Statistics
150 (39.5)
230 (60.5)
4.1 ± 4.2
4 (2 – 5)

122 (32.1)
258 (67.9)
170 ± 45.9
163 (137.25 –
97.75)

301 (79.2)
79 (20.8)
179.7± 94.3
155 (120 – 216)
180 (47.4)
200 (52.6)
85.3 ± 36.1
79 (60 - 105)
269 (70.8)
111 (29.2)
53.19 ± 13.48
51 (44 – 62)
113 (51.4)
107 (48.6)

46.93 ± 11.31
45 (39 – 53)
107 (66.9)
53 (33.1)

HCI: healthcare index; HDL: high density lipoprotein; LDL: low density lipoprotein
LDL, HDL, Triglycerides, and Total cholesterol are measured in mg/ dL
BMI: body mass index.

Clinical characteristics
The studied patients have a mean ± SD
of HbA1c of 8.3± 1.8. The median of HbA1c
was 8.05 with interquartile range of (Q1=

6.93; Q3= 9.5). The minimum recorded value
of HbA1c was 4.6 and the maximum
recorded value was 14.0%. The majority of
studied patients (278; 73.2%) had HbA1c
value above 7%. HbA1c values were not
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normally distributed with a normality test p
value less than 0.01. Clinical laboratory
investigation showed that more than two
thirds of the patients have hypertension (255;
67.1%) and more than one third reported
having diabetic complications in the form of
retinopathy and/ or cardiac complications
(150; 39.5%). The mean ± SD of total
cholesterol was 169.94 ± 46 mg/ dL with 79
(20.8%) of studied patients having total
cholesterol above 200 mg/ dL. For
triglycerides, the mean ± SD was 179.68 ±
94.32 with more than half of the studied
patients (200; 52.6%) having TG above 150
mg/ dL. For LDL, the mean ± SD was 85.26
± 36.10 mg/ dL with 111 (29.2%) patients
having LDL value ≥ 100 mg/ dL. For HDL
values, approximately one half of female
patients (107; 48.6%) had values that are
lower than recommended, while this was the
case in approximately one third of the male
patients (53; 33.1%). The healthcare index
(HCI) of the studied patients had a mean ±
SD of 4.29 ± 1.49 and a median of 4. The
range of HCI values was 0 to 7 with the
higher values indicating more concern about
health, frequent visits to clinics, frequent
weight and blood pressure measurement. A
total of 122 (32.11%) patients had an HCI of
≤ 3 while the remaining 67.89% had an HCI
score ≥ 4.
Univariate analysis
Demographic and clinical variables were
tested for significant relation with HbA1c

value. there was significant correlation
between HbA1c and the following
continuous variables: duration of illness
(p=0.02), triglycerides (p=0.024), age
(p<0.01), total cholesterol (p< 0.01), LDL
(p<0.01), HDL (p=0.028), HIC (p<0.01), and
type of therapeutic regimen (p<0.01). Age
was significantly and negatively correlated
with HbA1c value where older patients have
lower HbA1c values than younger ones. For
both cholesterol and LDL, there was
significant positive correlation with HbA1c.
For, HDL values, there was a significant
negative correlation with higher HDL values
were associated with lower HbA1c values.
For type of therapeutic regimen, patients on
oral anti-diabetic therapy had significantly
lower HbA1c than those on insulin therapy,
or the patients on insulin and oral antidiabetic therapy. There was no significant
difference in HbA1c value between those on
insulin therapy versus those on insulin and
oral anti-diabetic medications. No significant
difference was found in HbA1c values and
the following categorical variables: gender
(p=0.17) or smoking (p=0.35), or history of
hypertension (p=0.561) or presence of comorbid conditions (p=0.21). Similarly, there
was no significant correlation between
HbA1c and the following continuous
variables: BMI (p=0.57), diastolic blood
pressure (p=0.10), and systolic blood
pressure (p=0.90).(Table 2 & 3)

Table (2): Univariate analysis of demographic and clinical variables with HbA1c using Spearman
correlation.
Variable
HbA1c * Age
HbA1c * BMI
HbA1c * Duration
HbA1c * Systolic BP
HbA1c * Diastolic BP
HbA1c * Cholesterol
HbA1c * Triglyceride
HbA1c * LDL
HbA1c * HDL
HbA1c * HCI Score

p value

Correlation (r)

<0.01
0.57
0.02
0.90
0.10
<0.004
0.024
<0.001
0.028
0.006

-0.18
-0.03
0.12
0.007
0.08
0.15
0.14
0.167
-0.11
0.14

HCI: healthcare index; HDL: high density lipoprotein; LDL: low density lipoprotein; BMI: body mass index;
BP: blood pressure.
LDL, HDL, Triglycerides, and Total cholesterol are measured in mg/ dL
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Table (3): Univariate analysis of categorical variables with HbA1c
variable
Gender
Male
Female
Tobacco
Yes
No
Co-morbid conditions
Yes
No
History of HTN
Yes
No
Therapeutic regimen
Oral drugs
Insulin
Oral + Insulin

(HbA1c)
Mean ± SD

HbA1c
Median (Q1 – Q3)

p value*

8.42 ± 1.82
8.16 ± 1.77

8.1 (7.2 – 9.7)
8 (6.8 – 9.4)

0.17

8.38 ± 1.81
8.23 ± 1.79

8.0 (7.1 – 9.7)
8.2 (6.9 – 9.4)

0.35

8.39 ± 1.75
8.20 ±1.82

8.2 (7.0 – 9.70)
8.0 (6.9 – 9.4)

8.23 ± 1.76
8.35 ± 1.87

8.0 (6.9 – 9.4)
8.1 (7.2 – 9.7)

0.56

7.74 ± 1.69
8.52 ± 1.81
8.76 ± 1.73

7.5 (6.4 – 8.6)
8.4 (6.9 – 9.9)
8.5 (7.5 – 9.9)

< 0.001

0.21

HTN: hypertension
*Statistical tests used were Mann-Whitney and Kruskal Wallis test.

All independent variables were entered as
continuous variables except for the type of
therapeutic regimen which was used as
categorical with code 1 meaning oral antidiabetic therapy, code 2 meaning insulin
therapy, and code 3 meaning insulin and oral
anti-diabetic therapy. The outcome of the
regression was presented in Table 4.

Multivariate analysis
Linear regression was used to find
significant factors associated with increasing
levels of HbA1c. The dependent variable was
HbA1c value entered as a continuous
variable. Independent variables were those
which significant p values in univariate
analysis and included: age, cholesterol, LDL,
HDL, HCI, and type of therapeutic regimen.

Table(4): Multiple linear regression analysis of association between factors and HbA1c values
Variables
Age
Continuous (1-year
units)
Duration of DM
Continuous (1-year
units)
Therapeutic
regimen
Insulin + Oral
Oral
HCI score
Continuous
Total Cholesterol
Continuous
Triglycerides
Continuous
LDL
Continuous
HDL
Continuous

95.0% Confidence Interval
for B
Lower Bound Upper Bound

Unstandardized
Coefficients B

Standardized
Coefficients B

P

-0.029

-0.164

0.002

-0.047

-0.011

0.002

0.007

0.895

-0.022

0.025

0.477
Reference

0.237

0.000

0.262

0.693

0.072

0.059

0.256

-0.052

.195

0.009

0.220

0.117

-0.002

0.019

-0.001

-0.069

0.366

-0.004

0.002

0.001

0.026

0.830

-0.010

0.013

-0.019

-0.139

0.031

-0.037

-0.002

HCI: healthcare index
HDL: high density lipoprotein
LDL: low density lipoprotein
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The model indicated that factors
significantly associated with increasing levels
of HbA1c value were younger age, lower
HDL values, and combination therapy with
insulin.
DISCUSSION
This study was carried out to assess the
prevalence of glycemic control and the
factors that are significantly associated with
increasing levels of HbA1c among a sample
of Palestinian type 2 diabetic patients. The
design of this study was cross sectional and
therefore the results obtained in our study do
not indicate causality. The major results
obtained here was that the majority of studied
patients had poor glycemic control with
HbA1c value above 7. Furthermore, younger
age, use of combination therapeutic regimen
(concomitant insulin and oral hypoglycemic
agents), as well as low HDL levels were
main significant factors associated with
increasing values of HbA1c. The absence of
several patients’ characteristics as significant
factors associated with higher HbA1c values
is in agreement with a study conducted in
Netherlands among type 2 diabetic patients
which concluded that finding significant
predictors of poor glycemic control in
primary healthcare practice is difficult [41].
Our study showed that a large proportion
of diabetic patients had poor glycemic
control with HbA1c value above 7. Several
similar studies carried out in the Middle
Eastern region came with similar conclusion
where a large proportion of studied patients
had poor glycemic control. A study in Jordan
found that approximately 65% of diabetic
patients had HbA1c value above 7 [26].
Another study in Jordan came up with lower
percentage of people with poor glycemic
control but the results are still considered
high [42]. The HbA1c values in some Arab
gulf countries is higher than that reported in
Jordan and closer to the results presented in
our study [43-46]. The poor glycemic control
among Palestinian diabetic patients in this
study could be attributed to poor medication
or dietary adherence. A previous study
showed that medication adherence among
diabetic patients has detrimental effects on

glycemic control [47]. A study in Palestine
investigated the rate of medication adherence
among diabetic patients and came up with the
result that more than 60% of diabetic patients
in Palestine had poor or moderate adherence
to hypoglycemic agents which adversely
affected their glycemic control [30]. Another
study carried out in Palestine indicated that
more than 50% of Palestinian diabetic
patients had knowledge score less than 8 out
of 14 when measured using Michigan
diabetes knowledge test (MDKT) [37].
Advancing age has been reported by
other researchers to be associated with lower
HbA1c value [48, 49]. It is possible that with
advancing age, patients became more aware
of potential negative consequences of DM
and tried to be more adherent to diet and
medications to maintain a good glycemic
control. Regarding complicated regimens and
its association with higher HbA1c, it is
expected that people with higher HbA1c
level to be prescribed insulin and other
glycemic control medications [50]. Our study
showed that combination therapy including
insulin is significantly associated with
increasing HbA1c value which is an expected
result given that physicians tend to prescribe
combination therapy to lower HbA1c value
in patients with poor glycemic control.
Patients with combination therapy are usually
those with deteriorated glycemic control that
necessitates the use of more aggressive
therapy, including insulin, to control blood
glucose level to hinder the development of
diabetic complications. The finding regarding
the association of combination therapy with
higher HbA1c level is in agreement with
previous published studies which made
similar conclusion [26, 41].
Univariate analysis showed significant
association between HbA1c levels and
dyslipidemia which is consistent with
previously published reports. A study carried
out in type 2 diabetic patients showed that
there was a direct and significant correlation
between HbA1c and various types of lipids
including
total
cholesterol,
LDL,
triglycerides and HDL with inverse
correlation in the case of HDL [51]. Similar
finding were reported in other studies [52,
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53]. In our study, low HDL values were
significantly and inversely associated with
HbA1c values. A recent study showed that
good glycemic control is associated with
increased level of HDL [54]. It is important
here to clarify that the relationship between
HbA1c value and HDL levels does not mean
that high HDL levels causes lowering of
HbA1c. It could be the opposite and that the
poor glycemic control with high HbA1c is
causing the abnormal levels in HDL [55].

triglycerides; TC, total cholesterol; BMI,
body mass index; IRB, Institutional Review
Board; HCI, Healthcare index

Our study is the first to discuss the issue
of glycemic control among Palestinian
diabetic patients attending governmental
primary healthcare units. Palestinian diabetic
patients with governmental insurance might
not have the optimal access to medications or
healthcare needed for diabetic patients due to
the financial instability of the Palestinian
National Authority which affects the quality
of health services offered to diabetic patients,
as well as, other patients with chronic
diseases. However, there is no doubt that the
cross-sectional nature of our study and the
sample size drawn made our conclusion to be
of a pilot nature rather than a national result.
Furthermore, the causality of significant
factors with high HbA1c levels obtained in
this study remain questionable given the
cross-sectional design of the study. Finally,
the sample size and the use of a single center
to recruit patients are considered limiting
factors in this study.

Consent for publication

CONCLUSION
The majority of Palestinian diabetic
patients attending governmental primary
healthcare center had poor glycemic control
with younger patients having greater risk of
having higher HbA1c values. Attention
should be made to patients with dyslipidemia
since it is significantly associated with higher
HbA1c values. More than one third of the
diabetic patients were receiving combination
therapy of insulin and oral hypoglycemic
therapy indicative of deteriorating glycemic
control.
List of abbreviations
DM, Diabetes mellitus; HbA1c, glycated
hemoglobin; HDL, high density lioporotein;
LDL, low density lipoprotein; TG,
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